Published fact-check
Claim checked
“Of 16 patients in Balachandran’s trial, eight showed a dramatic immune response to the mRNA-based vaccine. Seven of the eight are alive and well six years after the trial began, a finding that was to be presented Monday at the American Association of Cancer Research meeting in San Diego.”
Published
New data from a clinical trial led by Dr. Vinod Balachandran at Memorial Sloan Kettering Cancer Center (MSK) indicates that an experimental mRNA-based vaccine for pancreatic cancer has produced lasting immune responses. Of the 16 patients in the trial, eight developed a strong immune response, and seven of those eight remain alive and well six years later. These findings were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on April 20, 2026.
6 reviewed sources behind this verdict.
Provides detailed reporting on the trial results, the specific patient counts, and the six-year survival data.
Official social media confirmation from Memorial Sloan Kettering Cancer Center regarding Dr. Balachandran's presentation and the trial's success.
Confirms the AACR 2026 meeting schedule and the specific date of the updates.
Used for: Presentation at AACR 2026.
Home / Health / New personalised mRNA vaccine may change pancreatic cancer outcomes. # New personalised mRNA vaccine may change pancreatic cancer outcomes. ## A personalised mRNA vaccine may help the immune system fight pancreatic cancer for years, with early trial data showing reduced recurrence in some patients. In an early clinical trial, some patients developed a powerful and lasting immune response that appears to keep their cancer at bay. Dr Vinod Balachandran from Memorial Sloan Kettering
trial of an mRNA tumor vaccine shows that 7/8 patients with pancreatic cancer, who mounted an immune response to the vaccine, are still alive 6 years later.
The claim is directly supported by reporting from multiple outlets and official social media posts from the involved institutions. Evidence from NBC Palm Springs and LinkedIn posts by Memorial Sloan Kettering confirms the specific statistics: 16 total patients, 8 with dramatic immune responses, and 7 of those 8 surviving at the six-year mark. The timing of the presentation (Monday, April 20, 2026) at the AACR Annual Meeting is also corroborated by the conference's own blog and program schedule.
Source quality: The evidence includes direct reporting from news organizations and official confirmation from the Memorial Sloan Kettering Cancer Center and the AACR conference program.
High